Futurology

Osimertinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that binds to certain mutant forms of EGFR (T790M, L858R, and exon 19 deletion) that predominate in non-small cell lung cancer (NSCLC) tumours following treatment with first-line EGFR-TKIs². It exhibits a nine-fold greater affinity for select EGFR-sensitizing and T790M-resistance mutations than to wild-type EGFR¹.

(1) . https://bing.com/search?q=osimertinib+mechanism+of+action. (2) DRUG NAME: Osimertinib - BC Cancer. http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Osimertinib_monograph.pdf. (3) Mechanism of Action – TAGRISSO® (osimertinib). https://www.tagrissohcp.com/moa.html. (4) Osimertinib: Uses, Interactions, Mechanism of Action | DrugBank Online. https://go.drugbank.com/drugs/DB09330. (5) Mechanisms of osimertinib resistance and emerging treatment ... - PubMed. https://pubmed.ncbi.nlm.nih.gov/32693293/.